Doseology Enters U.S. Market, Eyeing Growth in Oral Stimulant Pouch Category

KELOWNA, BC – March 11, 2026 – Doseology Sciences Inc., a company specializing in the burgeoning oral stimulant pouch market, has officially expanded its reach into the United States by commencing trading on the OTCQB Venture Market under the ticker symbol DOSEF. The move signals a pivotal step in the company's strategy to attract American investors and capitalize on a rapidly growing consumer trend toward smoke-free stimulant alternatives.

"The United States represents both the largest capital market and one of the most important consumer markets for modern oral stimulant products, and this milestone supports our long‑term growth strategy," stated Chris Jackson, Chief Executive Officer of Doseology Sciences Inc. in the company's announcement. He emphasized that the uplisting provides greater transparency for investors as the company executes its growth plans.

This strategic uplisting places Doseology on a more visible platform for U.S. investors, moving it into a market tier recognized for its higher standards of governance and financial reporting compared to lower-tiered over-the-counter markets. The move is designed to build credibility and improve liquidity as the company positions itself as a key innovator in a disruptive product category.

A Strategic Play for Transparency and Growth

The transition to the OTCQB is more than a change of stock ticker; it represents a commitment to enhanced corporate governance. To qualify for the OTCQB, companies must remain current in their financial reporting, undergo an annual verification and management certification process, and maintain a minimum bid price, among other criteria. These stringent requirements are designed to provide investors with a higher degree of confidence and transparency.

Bolstering this commitment to governance, Doseology recently appointed Larry Latowsky as the Executive Chairman of its Board of Directors. A seasoned executive with over 30 years of experience, Latowsky's background includes leading major Canadian retail and pharmaceutical entities. He notably served as President and CEO of Katz Group Canada, which operated 1,500 pharmacies including the Rexall and Pharma Plus chains, and was instrumental in its eventual multi-billion-dollar acquisition by McKesson Corporation. His deep experience in regulated industries, public company compliance, and scaling direct-to-consumer platforms like Well.ca is expected to be a critical asset as Doseology navigates its expansion.

"Trading on OTCQB aligns the Company with higher standards of financial reporting and disclosure, providing greater transparency and confidence for investors as we execute our long-term growth strategy," Jackson added.

Tapping into a Burgeoning Consumer Trend

Doseology's strategic maneuvers are timed to coincide with a seismic shift in consumer behavior. The oral pouch category—encompassing both nicotine and non-nicotine stimulants—has emerged as one of the fastest-growing segments in the consumer goods space. This growth is fueled by a consumer-led migration away from traditional delivery formats like combustible cigarettes, vapes, and sugary energy drinks toward more discreet, portable, and smoke-free options.

The market size is substantial and expanding rapidly. The global nicotine pouch market alone was valued at approximately $2.5 billion in 2024 and is projected by some analysts to surge past $7 billion by 2033. The caffeine pouch segment, while more nascent, is also on a steep growth trajectory, with estimates placing its value at $500 million in 2025 and projecting it to exceed $1.8 billion by 2033, growing at a CAGR of 15%.

This explosive growth has not gone unnoticed by industry giants. Global conglomerates like Philip Morris International and British American Tobacco have invested heavily in their own modern oral nicotine products, validating the market's long-term potential and accelerating consumer awareness of the pouch format.

A 'Pure-Play' Strategy in a Crowded Field

Amidst this booming market, Doseology is carving out a specific niche as an early "pure-play" public company focused on oral stimulant pouches, with a particular emphasis on caffeine and nicotine-alternative compounds. This focus distinguishes it from the large tobacco companies that are diversifying into nicotine pouches as an extension of their existing portfolios.

The company is pursuing a multi-faceted platform strategy that integrates product development, brand creation, and direct-to-consumer (DTC) distribution. A cornerstone of this strategy is its acquisition of the "Feed That Brain" brand in August 2025. Originally a line of nutritional supplements, Doseology has leveraged the brand to launch its own Nootropic Energy Pouches, which are now being sold directly to U.S. consumers through a pilot program on Amazon and a dedicated e-commerce site.

Beyond brand building, the company is investing in its technological future. It is actively exploring the development of proprietary intellectual property, including next-generation caffeine analog and nicotine-alternative compounds specifically designed for the unique demands of modern oral delivery systems. This focus on R&D is central to its goal of building a scalable and defensible ecosystem of functional stimulant products.

Navigating a Competitive and Evolving Landscape

While the opportunity is significant, the path forward is highly competitive. The nicotine pouch space is dominated by the well-capitalized brands of tobacco giants, including Swedish Match's ZYN and British American Tobacco's Velo. In the caffeine pouch segment, a growing number of agile brands like Grinds and Mojo are also vying for market share, indicating that a low barrier to manufacturing entry could lead to a crowded field.

The regulatory landscape presents another complex variable. While increased scrutiny on vaping and combustible tobacco benefits smoke-free alternatives, new product categories often exist in a regulatory gray area. Caffeine pouches, in particular, face ongoing debates in some regions regarding their classification and accessibility, while nicotine products in the U.S. must navigate the FDA's rigorous Premarket Tobacco Product Application (PMTA) process.

Guiding Doseology through these strategic and regulatory waters is where the experience of its leadership, particularly new Executive Chairman Larry Latowsky, becomes paramount. His track record of managing large-scale, regulated distribution networks and scaling consumer-facing health platforms provides the company with seasoned oversight as it aims to turn its strategic vision into tangible market share and long-term shareholder value.